Retatrutide

Human evidence can mean a controlled clinical study, an observational study, a safety or exposure report, or evidence from a particular finished formulation. Those are different kinds of information.

Limited human evidence. Some human evidence exists, but it is small, early, indirect, or limited to a particular formulation or population.

Preclinical means research in cells, tissues, or animals rather than in people. It can help researchers form a hypothesis, but it cannot establish a human benefit or a complete human safety profile.

Preclinical pharmacology supported development of a triple-receptor agonist, but animal and laboratory findings cannot establish clinical outcomes in people.[1]

Preclinical findings do not establish outcomes in people.

Risk information may describe the compound, a finished product, a route, a population, or product-quality concerns. The cited material does not replace a current product label or an individual professional assessment.

This section is about the United States only. Status applies to a product, formulation, route, population, and use—not to a name in the abstract. A status shown here is not a recommendation or a statement about another country.

• Source/status dateJul 22, 2026

  Investigational

  Retatrutide is not an FDA-approved drug. FDA has stated that it is not the active ingredient in an approved drug and does not qualify for the compounding exemptions discussed in its enforcement communication.

  Specific product form or route is not separately published in this status record.

  Open source context

The date above is the date attached to the published status record or source context. It is not necessarily the original approval date.

These prompts help organise a conversation with a qualified professional. They do not create a treatment recommendation, dose, or protocol.

• EvidenceWhich human evidence applies to the exact product, form, route, and use being discussed?
• What remains uncertainWhat is known, and what remains uncertain for this specific context?
• RisksWhich important warnings, common effects, and product-quality concerns should be discussed?
• U.S. statusWhat does the U.S. status cover, and what does it not cover?

Related means that the profiles share a topic, pathway, product context, or research question. It does not mean that they are equivalent.

• TirzepatideBoth engage GIP and GLP-1 receptors; retatrutide also targets glucagon receptors and remains investigational.

PeptideGrid review date: Jul 22, 2026. Sources support the specific sections that cite them. Publication does not imply endorsement, equivalence, or individual suitability.

1. 1

   Retatrutide phase 2 obesity trial

   Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial. New England Journal of Medicine. 2023.

   New England Journal of Medicine · Published Jun 26, 2023 · Accessed Jul 22, 2026 · Clinical study

   Open source
2. 2

   FDA warning letter addressing retatrutide products

   U.S. Food and Drug Administration. Warning letter stating that retatrutide is not the active ingredient in an FDA-approved drug and is not eligible for the cited compounding exemptions. 2025.

   U.S. Food and Drug Administration · Published Sep 9, 2025 · Accessed Jul 22, 2026 · Regulatory source

   Open source